Dana-Farber to offer first CAR T-cell therapy for mantle cell lymphoma after FDA approval

Today's Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy. Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) will be a certified treatment center for the therapy, known as Tecartus (brexucabtagene autoleucel, formerly KTE-X19).